Non Alcoholic Fatty Liver Disease Clinical Trial
Official title:
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
The central hypothesis of this proposal is that a reduction in hepatic mitochondrial
function is the main pathophysiology behind NAFLD (Non-Alcoholic Fatty Liver Disease) and
NASH (Non alcoholic steatohepatitis). The investigators further hypothesize that lifestyle
modifications through aerobic exercise training without weight loss or diet-induced weight
loss are effective in reducing NAFLD parameters by improving hepatic mitochondrial content
and function in human subjects.
The investigators propose a randomized, controlled human clinical trial to compare the
effects of aerobic exercise training (without weight loss) versus diet-induced weight loss
(without exercise) in individuals who have NAFLD or liver biopsy-confirmed NASH
Fatty Liver Disease) and NASH (Non alcoholic steatohepatitis). The investigators further
hypothesize that lifestyle modifications through aerobic exercise training without weight
loss or diet-induced weight loss are effective in reducing NAFLD parameters by improving
hepatic mitochondrial content and function in human subjects.
The investigators propose a randomized, controlled human clinical trial to compare the
effects of aerobic exercise training (without weight loss) versus diet-induced weight loss
(without exercise) in individuals who have NAFLD or liver biopsy-confirmed NASH
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
Completed |
NCT01277237 -
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT04442620 -
Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity
|
N/A | |
Completed |
NCT01999101 -
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
|
Phase 2 | |
Active, not recruiting |
NCT01482065 -
The Sleep, Liver Evaluation and Effective Pressure Study
|
N/A | |
Completed |
NCT03135873 -
Mastiha Treatment for Obese With NAFLD Diagnosis
|
N/A | |
Completed |
NCT02686476 -
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT02820285 -
Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH
|
N/A | |
Completed |
NCT01556113 -
Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
|
N/A | |
Recruiting |
NCT06080386 -
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
|
||
Terminated |
NCT02134522 -
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
|
N/A | |
Completed |
NCT01553500 -
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT05426382 -
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT03300661 -
Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine
|
N/A | |
Not yet recruiting |
NCT02178839 -
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
|
N/A | |
Recruiting |
NCT02038387 -
Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)
|
N/A | |
Completed |
NCT01874249 -
Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease
|
N/A | |
Completed |
NCT01634048 -
The Effect of Protein-enriched Diet on Body Composition and Appetite
|
N/A | |
Completed |
NCT01966627 -
Genetics of Fatty Liver Disease in Children
|
N/A | |
Terminated |
NCT01842282 -
Amlexanox for Type 2 Diabetes and Obesity
|
Phase 2 |